1 published article · Updated continuously
11 trials tracked for Erosive esophagitis: 7 in phase 3 or 4 and 5 with published results. The most-cited published study has 155 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Vonoprazan has demonstrated high rates of endoscopic healing for erosive esophagitis (EE) during an 8-week treatment phase, with reported success rates between 91.3% and 92.9% [4, 5]. During this same period, vonoprazan was associated with a significant difference in complete healing compared to other treatments (p<0.0001) 5. Additionally, vonoprazan showed high rates of endoscopic healing at earlier milestones, specifically at 2 weeks and 4 weeks 4.
Maintenance of EE healing using vonoprazan was observed through week 24, with success rates between 72.0% and 80.7% (p<0.0001) 5. However, recurrence of EE during the maintenance phase varies across studies; for example, one study reported a 13.3% recurrence rate at 24 weeks 6, while another showed a 27.8% recurrence rate at 12 weeks 6.
Other pharmacological interventions show varying efficacy in managing erosive esophagitis. Esomeprazole 40 mg was associated with significant rates of complete symptom relief (p<0.05) 2. Dexlansoprazole showed an 87.9% healing rate for EE by week 8 9. Lafutidine demonstrated specific recovery rates for reflux esophagitis and a proportion of days without 'cardinal symptoms' (p=0.05) 7.
Omeprazole/sodium bicarbonate was evaluated in patients with moderate (LA Grade C) and severe (LA Grade D) esophagitis; 83% and 81% of all subjects respectively improved or stayed the same after 8 weeks, with no statistically significant difference between groups (p=1.0) 3.
AI synthesis of 7 cited trials, updated Aug 17, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
